Tilray, Inc. Share Price Toronto S.E.
Equities
APHA
CA03765K1049
Pharmaceuticals
Sales 2024 * | 78Cr 106.96Cr 6.53TCr | Sales 2025 * | 86Cr 118.1Cr 7.21TCr | Capitalization | 160.43Cr 219.25Cr 13TCr |
---|---|---|---|---|---|
Net income 2024 * | -23Cr -31Cr -1.89TCr | Net income 2025 * | -8.5Cr -12Cr -709.41Cr | EV / Sales 2024 * | 2.28 x |
Net Debt 2024 * | 18Cr 24Cr 1.49TCr | Net Debt 2025 * | 11Cr 15Cr 905.54Cr | EV / Sales 2025 * | 1.98 x |
P/E ratio 2024 * |
-6.05
x | P/E ratio 2025 * |
-14
x | Employees | 1,600 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.73% |
Latest transcript on Tilray, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Irwin Simon
CEO | Chief Executive Officer | 65 | 30/21/30 |
Carl Merton
DFI | Director of Finance/CFO | - | 30/21/30 |
Lloyd Brathwaite
CTO | Chief Tech/Sci/R&D Officer | - | 30/21/30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Irwin Simon
CEO | Chief Executive Officer | 65 | 30/21/30 |
David Clanachan
BRD | Director/Board Member | 62 | 30/21/30 |
Walter Robb
BRD | Director/Board Member | 70 | 30/21/30 |
1st Jan change | Capi. | |
---|---|---|
+29.98% | 68TCr | |
+32.39% | 59TCr | |
-3.52% | 36TCr | |
+18.59% | 33TCr | |
+4.07% | 28TCr | |
+16.50% | 24TCr | |
+9.56% | 21TCr | |
-9.04% | 20TCr | |
+7.09% | 17TCr |